We are a pharmaceutical company with a mission to create best-in-class medicines for the treatment of addictions and drug overdose. Learn more about Opiant.
Location: United States, California, Santa Monica
Total raised: $50M
Investors 2
| Date | Name | Website |
| - | Medison Ve... | medisonven... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.12.2020 | - | $50M | - |
Mentions in press and media 20
| Date | Title | Description |
| 29.07.2025 | Hansa Biopharma announces key executive appointments to support continued growth | Hansa Biopharma announces key executive appointments to support continued growth Tue, Jul 29, 2025 18:00 CET Report this content Lund, Sweden, 29 July 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced three leadersh... |
| 04.12.2024 | Sinclair Announces New Executive Leadership to Support Global Growth Trajectory | Sinclair Sinclair is excited to announce the appointment of three dynamic leaders to its executive leadership team, marking a pivotal transition in propelling Sinclair into its next phase of growth, innovation, and market leadership. Frank ... |
| 25.01.2023 | Making naloxone available over the counter won’t solve the overdose crisis — but it will help | The Food and Drug Administration aims to conduct priority reviews of at least two product applications for granting over-the-counter status to intranasal formulations of naloxone, an overdose-reversal drug. Naloxone prevents overdose deaths... |
| 08.08.2022 | Opiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal Nalmefene | SANTA MONICA, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded an additional approximately $... |
| 25.01.2022 | Opiant Pharmaceuticals Announces Additional $2.2 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program | SANTA MONICA, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (“BARDA”) for an a... |
| 05.01.2022 | Teva and Novartis’ Sandoz launch Narcan generics on same day, brand marketer Emergent remains in play | Teva and Novartis’ Sandoz recently launched generic versions of Narcan on the same day, but it likely wasn’t a coincidence. Both first-to-market generics for Narcan, an opioid overdose rescue nasal spray, are FDA approve... |
| 12.11.2021 | Opiant Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update | SANTA MONICA, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results ... |
| 12.11.2021 | Opiant Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update - Form 8-K | Opiant Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update SANTA MONICA, Calif., November 11, 2021 -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical comp... |
| 25.10.2021 | Moon Rabbit Named Agency of Record by Opiant Pharmaceuticals | Opiant’s mission to develop new medicines for addictions and drug overdose represent a critical and essential advancement in the public health realm. Its potential new treatment for opioid overdose is something we are incredibly passionate ... |
| 05.08.2021 | Opiant Pharmaceuticals : Announces Second Quarter 2021 Financial Results and Provides Corporate Update | SANTA MONICA, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results ... |
Show more